Literature DB >> 26261646

Association between CTLA-4 gene polymorphism and ankylosing spondylitis: a case-control study.

Nai-Guo Wang1, Da-Chuan Wang1, Bing-Yi Tan1, Feng Wang1, Ze-Nong Yuan1.   

Abstract

AIMS: The aim of our study was to evaluate the association between CTLA-4 polymorphisms (+49A/G, -318C/T and CT60A/G) and ankylosing spondylitis (AS) susceptibility.
METHODS: A total of 120 AS cases and healthy controls, matched on the age and gender, were enrolled in the study. Polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) were used to determine the gentypes of +49A/G, -318C/T and CT60A/G polymorphisms. Genotype distribution in control group was assessed by Hardy Weinberg Equilibrium (HWE) test. Odds ratio (OR) with 95% confidence interval (95% CI) were adopted to evaluate the relationship of CTLA-4 polymorphisms and AS susceptibility.
RESULTS: In our study, genotype distribution of the three polymorphisms in control group was consistent with the HWE (P > 0.05). The genotype analysis showed that AA genotype of + 49A/G polymorphism could increase the risk for AS (OR=2.357, 95% CI=1.127-4.930). Moreover, the frequency of A allele was also presented as a risk factor for AS. Additionally, AA genotype and A allele of CT60A/G appeared to be related with AS susceptibility (OR=2.610, 95% CI=1.047-6.510; OR=1.751, 95% CI=1.160-2.641). However, the T allele of -318C/T appeared to be a protective factor for AS (OR=0.383, 95% CI=0.228-0.643).
CONCLUSION: In summary, there existed significant association between CTLA-4 gene polymorphisms and increased or decreased risk for AS.

Entities:  

Keywords:  +49A/G; -318C/T; CT60A/G; CTLA-4; ankylosing spondylitis

Mesh:

Substances:

Year:  2015        PMID: 26261646      PMCID: PMC4525980     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

2.  Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study.

Authors:  P Trontzas; A Andrianakos; S Miyakis; K Pantelidou; E Vafiadou; V Garantziotou; C Voudouris
Journal:  Clin Rheumatol       Date:  2005-04-29       Impact factor: 2.980

3.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

4.  Cytotoxic T-lymphocyte antigen 4 gene +49A/G polymorphism significantly associated with susceptibility to primary biliary cirrhosis: a meta-analysis.

Authors:  Rui Rui Chen; Zhe Yi Han; Jin Ge Li; Yong Quan Shi; Xin Min Zhou; Jing Bo Wang; Xi Qiang Cai; Xue Chang Wang; Ying Han; Dai Ming Fan
Journal:  J Dig Dis       Date:  2011-12       Impact factor: 2.325

Review 5.  HLA-B27 and genetic predisposing factors in spondyloarthropathies.

Authors:  J D Reveille; E J Ball; M A Khan
Journal:  Curr Opin Rheumatol       Date:  2001-07       Impact factor: 5.006

6.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

7.  CTLA-4 polymorphisms (+49 A/G and -318 C/T) are important genetic determinants of AITD susceptibility and predisposition to high levels of thyroid autoantibodies in Polish children - preliminary study.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska; Magdalena Rudzińska; Artur Bossowski; Anna Kucharska; Ewa Sewerynek; Karolina Czarnecka; Monika Migdalska-Sęk; Barbara Czarnocka
Journal:  Acta Biochim Pol       Date:  2013-12-20       Impact factor: 2.149

8.  Ankylosing spondylitis: current approaches to treatment.

Authors:  A Toivanen; T Möttönen
Journal:  BioDrugs       Date:  1998-09       Impact factor: 5.807

Review 9.  Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.

Authors:  Richard O Williams; Ewa Paleolog; Marc Feldmann
Journal:  Curr Opin Pharmacol       Date:  2007-07-12       Impact factor: 5.547

10.  Ctla-4 gene polymorphism in +49 a/g position: a case control study on patients with oral lichen planus.

Authors:  Jannan Ghapanchi; Mohammad Reza Haghshenas; Hamid Ghaderi; Sara Amanpour; Venus Nemati; Fereshteh Kamali
Journal:  J Int Oral Health       Date:  2014-09
View more
  3 in total

1.  Association of Genetic Variants in Pentraxin 3 Gene with Ankylosing Spondylitis.

Authors:  Xu Zhang; Wenyuan Ding
Journal:  Med Sci Monit       Date:  2016-08-18

2.  Association of Cytotoxic T Lymphocyte Antigen-4 Gene Polymorphisms with Psoriasis Vulgaris: A Case-Control Study in Turkish Population.

Authors:  Hatice Gül Dursun; Hüseyin Osman Yılmaz; Recep Dursun; Sevsen Kulaksızoğlu
Journal:  J Immunol Res       Date:  2018-04-23       Impact factor: 4.818

3.  The LMP2 CfoI polymorphism is associated with ankylosing spondylitis (AS) risk but not with acute anterior uveitis (AAU): A meta-analysis.

Authors:  Yufeng Qian; Bingqian Chen; Xiaowen Sheng; Yuqin Peng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.